EA201600354A1 - Антигенсвязывающая молекула, содержащая вариабельную область антитела - Google Patents
Антигенсвязывающая молекула, содержащая вариабельную область антителаInfo
- Publication number
- EA201600354A1 EA201600354A1 EA201600354A EA201600354A EA201600354A1 EA 201600354 A1 EA201600354 A1 EA 201600354A1 EA 201600354 A EA201600354 A EA 201600354A EA 201600354 A EA201600354 A EA 201600354A EA 201600354 A1 EA201600354 A1 EA 201600354A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- molecule
- antibody
- antigensound
- molecule containing
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
В заявке описано создание антигенсвязывающей молекулы, содержащей вариабельную область антитела, где молекула обладает связывающей активностью с молекулой, экспрессируемой на поверхности Т-клеток, и с молекулой, экспрессируемой на поверхности другого иммуноцита, но которая не связывается с обеими молекулами одновременно. В заявке описано также создание антигенсвязывающей молекулы, которая может предотвратить побочные эффекты, которые могут проявляться, когда сшиваются Т-клетки и другие иммуноциты, и которая обеспечивает получение антигенсвязывающей молекулы, пригодной для применения в качестве лекарственного средства.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013232803 | 2013-11-11 | ||
PCT/JP2014/079785 WO2015068847A1 (ja) | 2013-11-11 | 2014-11-11 | 改変された抗体可変領域を含む抗原結合分子 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201600354A1 true EA201600354A1 (ru) | 2016-12-30 |
Family
ID=53041619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201600354A EA201600354A1 (ru) | 2013-11-11 | 2014-11-11 | Антигенсвязывающая молекула, содержащая вариабельную область антитела |
Country Status (12)
Country | Link |
---|---|
US (3) | US20160280787A1 (ru) |
EP (1) | EP3070168A4 (ru) |
JP (3) | JPWO2015068847A1 (ru) |
KR (2) | KR20230104764A (ru) |
CN (3) | CN105940107B (ru) |
AU (1) | AU2014347565B2 (ru) |
BR (1) | BR112016010025A2 (ru) |
CA (1) | CA2929044A1 (ru) |
EA (1) | EA201600354A1 (ru) |
MX (1) | MX2016005762A (ru) |
TW (2) | TWI712421B (ru) |
WO (1) | WO2015068847A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6628966B2 (ja) | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
JPWO2015068847A1 (ja) | 2013-11-11 | 2017-03-09 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
TWI740809B (zh) * | 2014-11-11 | 2021-10-01 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
WO2016182064A1 (ja) | 2015-05-13 | 2016-11-17 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
CN118126180A (zh) | 2016-12-22 | 2024-06-04 | 第一三共株式会社 | 抗cd3抗体和包含所述抗体的分子 |
WO2018156106A1 (en) * | 2017-02-22 | 2018-08-30 | Ding Enyu | An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes |
AU2018243670A1 (en) * | 2017-03-31 | 2019-10-31 | The Regents Of The University Of California | Compositions and methods for targeting and killing ALPHA-V BETA-3-positive cancer stem cells (CSCs) and treating drug resistant cancers |
WO2019111871A1 (en) * | 2017-12-05 | 2019-06-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137 |
US20200399373A1 (en) * | 2018-02-14 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule and combination |
US20220033482A1 (en) * | 2018-02-19 | 2022-02-03 | New York University | Alpha-synuclein single domain antibodies |
WO2020067399A1 (en) * | 2018-09-28 | 2020-04-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
KR20210068079A (ko) * | 2018-09-28 | 2021-06-08 | 추가이 세이야쿠 가부시키가이샤 | Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자 |
CN114026119A (zh) * | 2019-06-28 | 2022-02-08 | 中外制药株式会社 | 结合pdgf-b和pdgf-d的抗原结合分子及其用途 |
CN112794914B (zh) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | 一种基于噬菌体展示技术开发的alk纳米抗体及其应用 |
KR102505383B1 (ko) | 2020-03-31 | 2023-03-02 | 추가이 세이야쿠 가부시키가이샤 | Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용 |
JP2023519776A (ja) * | 2020-03-31 | 2023-05-15 | 中外製薬株式会社 | 多重特異性抗原結合分子を製造するための方法 |
KR102365669B1 (ko) * | 2020-06-01 | 2022-02-23 | 머스트바이오 주식회사 | 이중특이 항체 또는 그의 항원-결합 단편 및 이를 제조하는 방법 |
WO2023081266A2 (en) * | 2021-11-03 | 2023-05-11 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Molecules that bind to protogenin (prtg) polypeptides |
CN116178567A (zh) * | 2022-10-28 | 2023-05-30 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US6955900B1 (en) * | 1993-02-02 | 2005-10-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
DE4419399C1 (de) | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
JP2002522029A (ja) | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | コートタンパク質の改変によるファージ提示における改良した形質転換効率 |
US20010036647A1 (en) | 1998-10-22 | 2001-11-01 | Prabhakara V. Choudary | Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof |
CN1237076C (zh) | 1999-01-15 | 2006-01-18 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
EP1706424B1 (en) | 2004-01-12 | 2009-07-22 | Applied Molecular Evolution, Inc. | Fc region variants |
US7534604B2 (en) * | 2004-01-16 | 2009-05-19 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
CN101014619B (zh) | 2004-07-15 | 2010-11-03 | 赞科股份有限公司 | 优化的Fc变体 |
CA2577329A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
DK1797127T3 (en) | 2004-09-24 | 2017-10-02 | Amgen Inc | Modified Fc molecules |
CN101123983A (zh) * | 2004-10-27 | 2008-02-13 | 米迪缪尼股份有限公司 | 特定修饰对相关抗原的亲和力来调节抗体的特异性 |
WO2006047639A2 (en) * | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
KR101019525B1 (ko) | 2004-11-12 | 2011-03-07 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
ATE548386T1 (de) | 2005-01-05 | 2012-03-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
CA2596248A1 (en) | 2005-01-31 | 2006-08-10 | Vaxinnate Corporation | Method to identify polypeptide toll-like receptor (tlr) ligands |
WO2006106903A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2構造異性体 |
EP1870459B1 (en) | 2005-03-31 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
CN101262885B (zh) * | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
AU2006256030B2 (en) | 2005-06-10 | 2012-06-21 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
US20080227958A1 (en) | 2006-04-14 | 2008-09-18 | Trubion Pharmaceuticals Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
JP2009537147A (ja) | 2006-05-15 | 2009-10-29 | シー レーン バイオテクノロジーズ, エルエルシー | インフルエンザウイルスに対する中和抗体 |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
JP2010524851A (ja) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
US8337854B2 (en) | 2007-04-04 | 2012-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Monoclonal antibodies against dengue and other viruses with deletion in Fc region |
MY180713A (en) | 2007-09-26 | 2020-12-07 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
ES2532461T3 (es) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | Variantes de FC con enlazamiento alterado a FCRN |
BRPI0907237A2 (pt) | 2008-01-11 | 2015-07-14 | Univ Tokyo | Anticorpo anti-cldn6 |
CA2713281C (en) | 2008-01-31 | 2019-10-15 | Dimiter S. Dimitrov | Engineered antibody constant domain molecules |
PL2708558T3 (pl) | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
CN102119332A (zh) | 2008-04-29 | 2011-07-06 | 免疫刺激公司 | 免疫调节组合物及其使用方法 |
CN102143977B (zh) * | 2008-09-03 | 2014-08-06 | 霍夫曼-拉罗奇有限公司 | 多特异性抗体 |
SI2334705T1 (sl) | 2008-09-26 | 2017-05-31 | Ucb Biopharma Sprl | Biološki produkti |
DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
NO2499161T3 (ru) | 2009-11-11 | 2018-02-03 | ||
PT2530091T (pt) | 2010-01-29 | 2018-05-17 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-dll3 |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
CA2808482C (en) | 2010-08-16 | 2021-10-26 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
CN108341868B (zh) | 2010-11-05 | 2022-06-07 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
CA2817015A1 (en) | 2010-11-09 | 2012-05-18 | Altimab Therapeutics, Inc. | Protein complexes for antigen binding and methods of use |
EP4279511A3 (en) | 2010-11-30 | 2024-01-24 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US20140080153A1 (en) | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
US9469685B2 (en) | 2011-01-10 | 2016-10-18 | Emory University | Antibodies directed against influenza |
CA2830254C (en) | 2011-03-16 | 2019-09-10 | Amgen Inc. | Fc variants |
WO2012143524A2 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
AU2012258087B2 (en) | 2011-05-13 | 2017-07-20 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
SI2714733T1 (sl) * | 2011-05-21 | 2019-06-28 | Macrogenics, Inc. | CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3 |
TWI687441B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
US9238689B2 (en) | 2011-07-15 | 2016-01-19 | Morpho Sys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) |
HUE038225T2 (hu) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák |
AU2012325915A1 (en) * | 2011-10-20 | 2014-04-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
HRP20211773T1 (hr) | 2011-11-04 | 2022-03-04 | Zymeworks Inc. | Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni |
RS56443B1 (sr) | 2012-02-24 | 2018-01-31 | Abbvie Stemcentrx Llc | Ddl3 modulatori i postupci primene |
EP2857420B1 (en) | 2012-05-30 | 2020-09-23 | Chugai Seiyaku Kabushiki Kaisha | Target-tissue-specific antigen-binding molecule |
JP6628966B2 (ja) | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
RU2678127C2 (ru) | 2012-11-13 | 2019-01-23 | Бионтех Аг | Агенты для лечения экспрессирующих клаудин раковых заболеваний |
WO2014075697A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
DK2940135T5 (da) | 2012-12-27 | 2021-09-20 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
MX2015012709A (es) | 2013-03-14 | 2016-05-31 | Macrogenics Inc | Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas. |
SG11201603397QA (en) | 2013-11-06 | 2016-05-30 | Stemcentrx Inc | Novel anti-claudin antibodies and methods of use |
JPWO2015068847A1 (ja) | 2013-11-11 | 2017-03-09 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
WO2015146438A1 (ja) | 2014-03-26 | 2015-10-01 | 国立大学法人東北大学 | ヒト上皮増殖因子受容体を標的とした二重特異性抗体 |
BR112016022912A2 (pt) | 2014-04-07 | 2017-10-17 | Chugai Pharmaceutical Co Ltd | molécula de ligação ao antígeno de imunoativação |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
TWI740809B (zh) * | 2014-11-11 | 2021-10-01 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
WO2019111871A1 (en) | 2017-12-05 | 2019-06-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137 |
WO2019131988A1 (en) | 2017-12-28 | 2019-07-04 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
JP2021510064A (ja) | 2018-01-05 | 2021-04-15 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
KR20210068079A (ko) | 2018-09-28 | 2021-06-08 | 추가이 세이야쿠 가부시키가이샤 | Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자 |
WO2020067399A1 (en) | 2018-09-28 | 2020-04-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
MX2022012092A (es) | 2020-03-31 | 2022-10-13 | Chugai Pharmaceutical Co Ltd | Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos. |
KR102505383B1 (ko) | 2020-03-31 | 2023-03-02 | 추가이 세이야쿠 가부시키가이샤 | Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용 |
JP2023519776A (ja) | 2020-03-31 | 2023-05-15 | 中外製薬株式会社 | 多重特異性抗原結合分子を製造するための方法 |
AR121692A1 (es) | 2020-03-31 | 2022-06-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas |
-
2014
- 2014-11-11 JP JP2015546719A patent/JPWO2015068847A1/ja not_active Withdrawn
- 2014-11-11 CA CA2929044A patent/CA2929044A1/en active Pending
- 2014-11-11 MX MX2016005762A patent/MX2016005762A/es unknown
- 2014-11-11 KR KR1020237022012A patent/KR20230104764A/ko not_active Application Discontinuation
- 2014-11-11 EP EP14859814.7A patent/EP3070168A4/en active Pending
- 2014-11-11 TW TW108101781A patent/TWI712421B/zh active
- 2014-11-11 BR BR112016010025A patent/BR112016010025A2/pt active Search and Examination
- 2014-11-11 CN CN201480072799.3A patent/CN105940107B/zh active Active
- 2014-11-11 US US15/035,098 patent/US20160280787A1/en not_active Abandoned
- 2014-11-11 EA EA201600354A patent/EA201600354A1/ru unknown
- 2014-11-11 CN CN202110577978.4A patent/CN113307873A/zh active Pending
- 2014-11-11 CN CN202110579555.6A patent/CN113278076A/zh active Pending
- 2014-11-11 TW TW103138989A patent/TWI652279B/zh active
- 2014-11-11 KR KR1020167015015A patent/KR102551410B1/ko active IP Right Grant
- 2014-11-11 WO PCT/JP2014/079785 patent/WO2015068847A1/ja active Application Filing
- 2014-11-11 AU AU2014347565A patent/AU2014347565B2/en active Active
-
2019
- 2019-12-05 US US16/704,464 patent/US11739149B2/en active Active
-
2020
- 2020-08-25 JP JP2020141381A patent/JP2020196741A/ja active Pending
-
2022
- 2022-10-20 JP JP2022168321A patent/JP2022191448A/ja active Pending
-
2023
- 2023-06-30 US US18/345,750 patent/US20240026000A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2016005762A (es) | 2016-08-19 |
US11739149B2 (en) | 2023-08-29 |
US20200332001A1 (en) | 2020-10-22 |
CN113307873A (zh) | 2021-08-27 |
KR102551410B1 (ko) | 2023-07-04 |
CA2929044A1 (en) | 2015-05-14 |
JPWO2015068847A1 (ja) | 2017-03-09 |
CN105940107B (zh) | 2021-06-15 |
WO2015068847A1 (ja) | 2015-05-14 |
TW201919701A (zh) | 2019-06-01 |
CN113278076A (zh) | 2021-08-20 |
TW201605900A (zh) | 2016-02-16 |
EP3070168A4 (en) | 2017-06-28 |
CN105940107A (zh) | 2016-09-14 |
AU2014347565B2 (en) | 2020-08-13 |
JP2022191448A (ja) | 2022-12-27 |
EP3070168A1 (en) | 2016-09-21 |
BR112016010025A2 (pt) | 2017-12-05 |
JP2020196741A (ja) | 2020-12-10 |
TWI652279B (zh) | 2019-03-01 |
KR20160083094A (ko) | 2016-07-11 |
TWI712421B (zh) | 2020-12-11 |
KR20230104764A (ko) | 2023-07-10 |
US20240026000A1 (en) | 2024-01-25 |
US20160280787A1 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201600354A1 (ru) | Антигенсвязывающая молекула, содержащая вариабельную область антитела | |
CY1120637T1 (el) | Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40 | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
MX2022012089A (es) | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos. | |
EA201501063A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
EA201591806A1 (ru) | Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201591467A1 (ru) | Анти-lag-3 связывающие белки | |
EA201890278A1 (ru) | Антитела к pd-l1 | |
EA202192165A1 (ru) | Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201490717A1 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
EA201692287A1 (ru) | Антигенсвязывающая молекула, перенаправляющая т-клетки на клетки, обладающие иммуносупрессорной функцией | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
EA201400991A1 (ru) | Комбинированная терапия с использованием антител к человеческому csf-1r и ее применения | |
EA201300978A1 (ru) | Антитела к сеа | |
EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
EA201400579A1 (ru) | Антитела к il-36r | |
MX2021007663A (es) | Molecula de union al antigeno especifico para el tejido objetivo. | |
CL2020000233A1 (es) | Anticuerpos anti-cd137. | |
EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
EA201201016A1 (ru) | Антидоты антикоагулянтов | |
EA201592076A1 (ru) | Антитела против cd38 и слитые белки с ослабленным интерфероном альфа-2b |